Baird analyst Brian Skorney lowered the firm’s price target on Mirum Pharmaceuticals to $34 from $38 and keeps an Outperform rating on the shares. The firm noted the EMBARK trial of Livmarli in biliary atresia missed its primary and secondary endpoints, which is disappointing as it removes an important driver of the upside thesis for the drug. As a result of removing the opportunity from the model, Baird lowered the price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIRM:
- 3 Best Stocks to Buy Now, 12/19/2023, According to Top Analysts
- Cantor Fitzgerald biotech analyst holds an analyst/industry webinar
- Mirum Pharmaceuticals reinstated with an Overweight at JPMorgan
- Mirum reports new data from LIVMARLI and volixibat programs presented at meeting
- Mirum Pharmaceuticals initiated with an Overweight at Morgan Stanley
